Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region: First Asian Pacific working party on functional dyspepsia

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue 4, 1998, Pages 335-353

  Talley, Nicholas J ^a   Lam, S K ^b   Goh, K L ^c   Fock, K M ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF MALAYA   (Malaysia)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Antisecretory cisapride; Domperidone; Endoscopy; Functional dyspepsia; H. pylori; Management trials; Non ulcer dyspepsia; Prokinetic; Proton pump inhibitor

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTACID AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; BISMUTH; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; CLARITHROMYCIN; DIMETRIDAZOLE; DOMPERIDONE; ERYTHROMYCIN; GONADORELIN DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; METRONIDAZOLE; NITRIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROKINETIC AGENT; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; RANITIDINE; SOMATOSTATIN; STOMACH SECRETION INHIBITOR; SUCRALFATE; SULPIRIDE; TINIDAZOLE; UNINDEXED DRUG;

ABDOMINAL PAIN; ASIA; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DYSPEPSIA; ENDOSCOPY; GASTRODUODENAL ULCER; GASTROESOPHAGEAL REFLUX; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; PACIFIC ISLANDS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STOMACH CARCINOMA;

EID: 0031976964     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1998.tb00644.x     Document Type: Review

References (123)

1. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ III. Dyspepsia and dyspepsia subgroups: A population-based study. Gastroenterology 1992; 102: 1259-68.
2. Jones R, Lydeard SE, Hobbs FD et al. Dyspepsia in England and Scotland. Gut 1990; 31: 401-5.
3. Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ III. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am. J. Epidemiol. 1992; 15: 165-77.
4. Jones R, Lydeard S. Dyspepsia in the community: a follow-up study. Br. J. Clin. Pract. 1992; 46: 95-7.
5. Knill-Jones RP. Geographical differences in the prevalence of dyspepsia. Scand. J. Gastroenterol. 1991; 26 (Suppl 182): 17-24.
6. Drossman DA, Li Z, Andruzzi E et al. Householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig. Dis. Sci. 1993; 38: 1569-80.
7. Richter JE. Dyspepsia: Organic causes and differential characteristics from functional dyspepsia. Scand. J. Gastroenterol. (Suppl) 1991; 182: 11-16.
8. Talley NJ, Weaver AL, Tesmer DL, Zinsmeister AR. Lack of discriminant value of dyspepsia subgroups in patients referred for upper Gastroenterology 1993; 105: 1378-86.
9. Schlemper RJ, Van Der Werf SD, Biemond I, Lamers C BHJ. Dyspepsia and Helicobacter pylori in Japanese employees with and without ulcer history. J. Gastroenterol. Hepatol. 1995; 10: 633-8
10. Kiyota K. Epidemiology of non-ulcer dyspepsia (NUD) in Japan: Nippon Shokakibyo Gakkai Zasshi 1992; 89: 1973-81.
11. Inoue M, Sekiguchi T, Harasawa S, Miwa T, Miyoshi A. Dyspepsia and dyspepsia subgroups in Japan: Symptom profiles and experience with cisapride. Scand. J. Gastroenterol. 1993; 195 (Suppl): 36-8.
12. Talley NJ, Colin-Jones D, Koch KJ, Koch M, Nyrén O, Stanghellini V. Functional dyspepsia: A classification with guidelines for diagnosis and management. Gastroenterol. Int. 1991; 4: 145-60.
13. Heading RC. Definitions of dyspepsia. Scand. J. Gastroenterol. 1991; 26 (Suppl 182): 1-6.
14. Holtmann G, Talley NJ. Functional dyspepsia: Current treatment recommendations. Drugs 1993; 45: 918-30.
15. Talley NJ, Silverstein M, Agreus L, Nyrén O, Sonnenberg A, Holtmann G. Evaluation of dyspepsia. Gastroenterology 1998 (in press).
16. Lam SK, Talley NJ. Asian-Pacific Consensus Guidelines on the management of H. pylori. J. Gastroenterol. Hepatol. 1998; 13: 1-12.
17. Health and Public Policy Committee. Endoscopy in the evaluation of dyspepsia. Ann. Intern. Med. 1985; 102: 266-9.
18. Anonymous. Management of dyspepsia: report of a working party. Lancet 1988; 1: 576-9.
19. McCarthy S, Chia YC, Goh KL. Epidemiology of dyspepsia in a Primary Care Unit of a multiracial society. J. Gastroenterol. Hepatol. 1996; 11 (Suppl. 2): A67.
20. DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology. Arch. Intern. Med. 1995; 155: 2165-73.
21. Klauser AG, Schindlbeck NE, Müller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990; 335: 205-8.
22. Small PK, Loudon MA, Waldron B, Smith D, Campbell FC. Importance of reflux symptoms in functional dyspepsia. Gut 1995; 36: 189-92.
23. Nyrén O. Secretory abnormalities in functional dyspepsia. Scand. J. Gastroenterol. 1991; 182 (Suppl.): 25-8.
24. El-Omar E, Penman I, Ardill JE, McColl KE. A substantial proportion of non-ulcer dyspepsia patients have the same abnormality of secretion as duodenal ulcer patients. Gut 1995; 36: 534-8.
25. George AA, Tsuchiyose M, Dooley CP. Sensitivity of the gastric mucosa to acid and duodenal contents in patients with non-ulcer dyspepsia. Gastroenterology 1991; 101: 3-6.
26. Talley NJ, Hunt RH. What role does Helicobacter pylori play in non-ulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology 1997; 113 (Suppl. 6): S67-77.
27. Laheij RJF, Jansen JBMJ, Van de Lisdonk EH, Severens JL, Verbeek ALM. Review article: Symptom improvement through eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment. Pharmacol. Ther. 1996; 10: 843-50.
28. Agréus L, Talley N. Dyspepsia management in general practice. BMJ 1997; 315: 1284-8.
29. McColl KE, El-Nujumi A, Murray L et al. The Helicobacter pylori breath test: A surrogate marker for peptic ulcer disease in dyspeptic patients. Gut 1997; 40: 302-6.
30. Hansson LR, Engstrand L, Nyrén O, Lindgren A. Prevalence of Helicobacter pylori infection in subtypes of gastric cancer. Gastroenterology 1995; 109: 885-8.
31. Quigley EMM. Motility, heartburn and dyspepia. Aliment. Pharmacol. Ther. 1997; 11 (Suppl 2): 41-50.
32. Stanghellini V, Tosetti C, Paternico A et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996; 110: 1036-42.
33. Mearin F, de Ribot X, Balboa A et al. Does Helicobacter pylori infection increase gastric sensitivity in functional dyspepsia? Gut 1995; 37: 47-51.
34. Parkman HP, Miller MA, Trate D et al. Electogastrography and gastric emptying are complementary for assessment of dyspepsia. J. Clin. Gastroenterol. 1997; 24: 214-19.
35. Coffin B, Azpiroz F, Guarner F, Malagelada JR. Selective gastric hypersensitivity and reflex hyporeactivity in functional dyspepsia. Gastroenterology 1994; 107: 1345-51.
36. Holtmann G, Goebell H, Talley NJ. Impaired small intestinal peristaltic reflexes and sensory thresholds are independent functional disturbances in patients with chronic unexplained dyspepsia. Am. J. Gastroenterol. 1996; 91: 485-91.
37. Mayer EA. Gut feelings: What turns them on? Gastroenterology 1995; 108: 927-31.
38. Talley NJ, Phillips SF, Bruce B, Twomey CK, Zinsmeister AR, Melton LJ III. Relation among personality and symptoms in non-ulcer dyspepsia and the irritable bowel syndrome. Gastroenterology 1990; 99: 327-33.
39. Jonsson BH, Theorell T, Gotthard R. Symptoms and personality in patients with chronic functional dyspepsia. J. Psychosom. Res. 1995; 39: 93-102.
40. Hui WM, Lam SK.The perception of life events and daily stress in non-ulcer dyspepsia. Am. J. Gastroenterol. 1991; 86: 292-6.
41. Haug TT, Wilhelmsen I, Berstad A, Ursin H. Life events and stress in patients with functional dyspepsia compared with patients with duodenal ulcer and healthy controls. Scand. J. Gastroenterol. 1995; 30: 524-30.
42. Elta GH, Behler EM, Colturi TJ. Comparison of coffee intake and coffee-induced symptoms in patients with duodenal ulcer, non-ulcer dyspepsia and normal controls. Am. J. Gastroenterol. 1990; 85: 1339-42.
43. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ III. Smoking, alcohol and analgesics in dyspepsia and among dyspepsia subgroups: lack of association in a community. Gut 1994; 35: 619-24.
44. Barnes RJ, Gear MW, Nicol A, Dew AB. Study of dyspepsia in a general practice as assessed by endoscopy and radiology. BMJ 1974; 4: 214-16.
45. Kerrigan D, Brown S, Hutchison G. Open access gastroscopy: Too much to swallow? BMJ 1990; 300: 374-6.
46. Hungin A, Thomas P, Bramble M et al. What happens to patients following open access gastroscopy? An outcome study from general practice. Br. J. Gen. Pract. 1994; 44: 519-21.
47. Møller Hansen J, Bytzer P, Bondesen S, Schaffalitzky de Muckadell OB. Efficacy and outcome of an open access endoscopy service. Dan. Med. Bull. 1991; 38: 288-90.
48. Bytzer P, Hansen JM, Schaffalitzky de Muckadell OB. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994; 343: 811-16.
49. Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol. Clin. North Am. 1996; 25: 373-96.
50. Chia KS, Lee HP, Seow A, Shanmugaratnam K. Cancer incidence in Singapore 1968-1992. Singapore Cancer Registry, Report No. 4. 1992; 74.
51. Jones RH, Baxter G. Lansoprazole 30mg daily versus ranitidine 150mg b.d. in the treatment of acid related dyspepsia in general practice. Aliment. Pharmacol. Ther. 1997; 11: 541-6.
52. Müller P, Hotz J, Franz E, Simon B. Ranitidine in the treatment of non-ulcer dyspepsia, a placebo controlled study in the Federal Republic of Germany. Arzneimittelforschung. 1994; 44: 1130-2.
53. Johannessen T, Petersen H, Kristensen P et al. Cimetidine on-demand in dys-pepsia. Experience with randomised controlled single-subject trials. Scand. J. Gastroenterol. 1992; 27: 189-95.
54. Misra SP, Dwiredi M, Misra V, Agarwal SK. Sucralfate versus ranitidine in non-ulcer dyspepsia: Results of a prospective, randomised, open controlled trial. Indian J. Gastroenterol. 1992; 11: 7-8.
55. Johannessen T, Kristensen P, Petersen H et al. The symptomatic effect of one day treatment periods with cimetidine in dyspepsia. Combined results from randomised, controlled, single-subject trials. Scand. J. Gastroenterol. 1991; 26: 974-80.
56. Hotz J, Plein K, Bunke R. The effectiveness of ranitidine in non-ulcer dyspepsia (functional dyspepsia). Medizinische Klinik. 1994; 89: 73-80.
57. Jebbink HJ, Smout AJ, van Berge Henegouwen GP. Ranitidine therapeutically effective in functional dyspepsia with reflux-like symptoms. Nederland Tijdschrift voor Geneeskunde. 1993; 137: 1772-5.
58. Talley NJ, Meineche-Schmidt V, Paré P et al. Is acid suppression efficacious in non-ulcer dyspepsia? A double blind, randomised controlled trial with omeprazole. Gastroenterology 1998; 114: A (in press).
59. Champion MC, Maccannell KL, Thomson ABR et al. A double-blind randomized study of cisapride in the treatment of non-ulcer dyspepsia. Can. J. Gastroenterol. 1997; 11: 127-34.
60. De Groot GH, De Both PSM. Cisapride in functional dyspepsia in general practice. A placebo-controlled, randomized, double-blind study. Aliment. Pharmacol. Ther. 1997; 11: 193-9.
61. Yeoh KG, Kang JY, Tay HH et al. Effect of cisapride on functional dys-pepsia in patients with and without histological gastritis: A double-blind placebo controlled trial. J. Gastroenterol. Hepatol. 1997; 12: 13-18.
62. Eberl T, Fischer J, Barnert J, Wienbeck M. Cisapride in functional dyspepsia: does it affect gastric tone? Neurogastroenterol. Motil. 1996; 8: 170.
63. Al-Quorain A, Larbi EB, Al-Shedoki F. A double-blind, randomized placebo-controlled trial of cisapride in Saudi Arabs with functional dyspepsia. Scand. J. Gastroenterol. 1995; 30: 531-4.
64. Kiyota K, Inokuchi H, Habu Y, Hirota M, Kawai K. Clinical evaluation of cisapride and cimetidine in non-ulcer dyspepsia. Ther. Res. 1995; 16: 1899-904.
65. Baoen W, Xiaomei L, Boqi J et al. A controlled multicentre clinical trial on cisapride in treatment of functional dyspepsia. Chin. J. Int. Med. 1995; 34: 180-4.
66. Kellow JE, Cowan H, Shuter B et al. Efficacy of cisapride therapy in functional dyspepsia. Alimem. Pharmacol. Ther. 1905; 9: 153-60.
67. Hansen JM, Bytzer P, Schaffalitzky de Muckodell OB. Placebo-controlled trial of cisapride and nizatidine in unselected patients with non-ulcer dys-pepsia. Gastroenterology 1994; 106: 89.
68. Wood SF, Denney SC, Cochran KM. Cisapride in functional dyspepsia: a double-blind, placebo-controlled randomized trial in general practice patients. Scand. J. Gastroenterol. 1993; 28: 5-10.
69. Chung JM. Cisapride in chronic dyspepsia: result of a double-blind, placebo-controlled trial. Scand. J. Gastroenterol. 1993; 28: 11-14.
70. Van Outryve M, De Nutte N, Van Eeghen P, Gooris JP. Efficacy of cisapride in functional dyspepsia resistant to domperidone or metocloprimide: a double-blind, placebo-controlled study. Scand. J. Gastroenterol. 1993; 28: 47-53.
71. Hausken T, Berstad A. Cisapride treatment of patients with non-ulcer dyspepsia and erosive prepyloric changes. A double-blind, placebo-controlled trial. Scand. J. Gastroenterol. 1992; 27: 213-17.
72. Marzio L, Difelice F, Laico ML et al. Gallbladder hypokinesia and normal gastric emptying of liquids in patients with dyspeptic symptoms. A double-blind placebo-controlled clinical trial with cisapride. Dig. Dis. Sci. 1992; 37: 262-7.
73. Agorastos et al. Effect of cisapride in nonulcer dyspepsia. A placebo controlled trial. Curr. Ther. Res. 1991; 49: 870-7.
74. Testoni PA, Bagnolo F, Fanti L, Passaretti, S, Tittobello A. Long-term oral cisapride improves interdigestive antroduodenal motility in dyspeptic patients, Gut 1990; 31: 286-90.
75. Halter F, Staub P, Hammer B, Guyot J, Miazza BM. Study with two prokinetics in functional dyspepsia and GORD: domperidone versus cisapride. J Physiol. Pharmacol. 1997; 48: 185-92.
76. Xiong Q, Qin OY, Chaoxin Y. Evaluation of therapeutic effectiveness of cisapride in functional dyspepsia. Chin. Natl J. New Gastroenterol. 1996; 2: 143.
77. Thor P, Plebankiewiez S, Lorens K, Konturek SJ. Effects of prokinetics treatment on gastric myoelectri activity and emptying in non-ulcer dysmotility- like dyspepsia. Neurogastroenterol. Motil. 1996; 8: 194.
78. Carvalhinhos A, Fidalgo P, Freire A, Matos L. Cisapride compared with ranitridine in the treatment of functional dyspepsia. Eur. J. Gastroenterol. Hepatol. 1995; 7: 411-17.
79. Halter F, Miazza B, Brignoli R. Cisapride or cimetidine in the treat-ment of functional dyspepsia. Results of a double-blind, randomized, Swiss multicentre study. Scand. J. Gastroenterol. 1994; 29: 618-23.
80. Fumagalli I, Hammer B. Cisapride versus metocloprimide in the treatment of functional dyspepsia. A double-blind comparative trial. Scand. J. Gastroenterol. 1994; 29: 33-7.
81. Grossi L, Di Felice F, Marzio L. Efficacia e tollerabilita di cisapride, granulato effervescente 10mg, nel trattamento della dispepsia funzionale. La Clinica Terapeutica, 1993; 142: 521-27 (in Italian).
82. Archimandritis A, Tzivras M, Fertakis A et al. Cisapride, metoclopramide and ranitidine in the treatment of severe non-ulcer dyspepsia. Clin. Ther. 1992; 14: 553-61.
83. Changhua W, Aixiu D, Xingjin L et al. Cisapride in treatment of functional dyspepsia in 71 patients. Chin. Natl J. New Gastroenterol. 1996; 2 (Suppl 1): 137.
84. Bosseckert H. Cisapride in functional dyspepsia. Gut 1905; 37 (Suppl 2): A139.
85. Furman SN, Cheetham RF, Becker PJ, Nixon V. Demographic, socioeconomic, and stress factors in patients with upper gastrointestinal symptoms (dyspepsia): impact on the therapeutic response to cisapride. Curr. Ther. Res. 1995; 56: 545-55.
86. Riezzo G, Cucchiara S, Chiloiro M, Minella R, Guerra V, Giorgio I. Gastric emptying and myoelectrical activity in children with non-ulcer dyspepsia. Effect of cisapride. Dig. Dis. Sci. 1995; 40: 1428-34.
87. Dollinger HC. Treatment of functional dyspepsia with cisapride: Results of a German multicentre trial. Gut 1994; 35 (Suppl. 4): A74.
88. Roesch W. Chronic functional dyspepsia: short- and medium-term outcome of a therapeutic trial with cisapride. Clin. Ther. 1994; 16: 437-45.
89. Takayasu et al. Meaning of gastric emptying measurement and therapeutic effect of gastrointestinal prokinetics in the treatment of patients with non-ulcer dyspepsia. Ther. Res. 1994; 15: 2454-60.
90. Kamiya et al. Gastric motility in non-ulcer dyspepsia. The Clinical Report 1994; 28: 1627-31.
91. Garibay JM. Cisaprida en el tratamiento de los trastornos de la motilidad del tubo digestivo. Investigaction Medica Internacional. 1993; 19: 151-8 (In Spanish with English abstract).
92. Hazelhoff B. Cisapride in the treatment of gastroesophageal reflux and of dyspepsia: A Dutch multicentre trial. In: Heading RC, Wood JD, eds. New York: Raven Press, Gastrointestinal Dysmotility: Focus on cisapride. 1992; 333.
93. Dunbar F. Presentation and treatment of dyspepsia. Curr. Ther. Res. 1992; 52: 349-53.
94. Corazza GR, Biagi F, Albano O et al. Levosulpiride in functional dyspepsia: A multicentre, double-blind controlled trial. Ital. J. Gastroenterol. 1996; 28: 317-23.
95. Mangiameli A, Brogna A, Catanzaro R, Sofia M, Blasi A. Levosulpiride versus domperidone in the treatment of functional dyspepsia. La Clinica Therapeutica 1994; 144: 107-14.
96. Duan LP, Zheng ZT, Li YN. Study of gastric emptying in non-ulcer dyspepsia using a new ultrasonographic method. Scand. J. Gastroenterol. 1993; 28: 355-60.
97. Gatto G, Ricca T, Randazzo MA et al. Clinical efficacy and safety of levosulpiride and domperidone in the management of chronic functional dyspepsia: a double-blind randomized clinical trial. Curr. Ther. Res. 1992; 51: 715-22.
98. Tatsuta M, Iishi H, Nakaizumi A, Okuda S. Effect of treatment with cisapride alone or in combination with domperidone on GE and gastro-intestinal symptoms in dyspeptics. Aliment. Pharmacol. Ther. 1992; 6: 221-8.
99. Fenying H, Biao L, Hongkuan Z. Gastric motor in NUD and clinical observation on treatment with domperidone. Chin. Natl J. New Gastroenterol. 1996; 2 (Suppl 1): 133.
100. Cutts TF, Abell TL, Karas JG, Kuns J. Symptom improvement from prokinetic therapy corresponds to improved quality of life in patients with severe dyspepsia. Dig. Dis. Sci. 1996; 41: 1369-78.
101. Tochihara M et al. Clinical effect of combine Acenalin and Nauzelin in gastrointestinal symptoms associated with chronic gastritis: Based on the changes of blood concentration of acetaminophen. Med. Consult. New Remed. 1993; 30: 65-70.
102. Halter F, Staub P, Meyer M. Triage, probatorische therapie und nachfolgekontrolle bei oberbauch-beschwerden. Zwischenalayse einer prospektiven studie. In: Weinbeck M et al., eds. Aktuelle Aspekte der Gastrointestinalen Motilitaet. Jena: Universitaetsverlag Jena GMBH 1993; 115-17 (in German).
103. Ovartlarnporn B, Ratanalert S, Keowkarnkar W. Liquid meal emptying in non-ulcer dyspepsia: a study in 22 Thai patients. J. Med. Assoc. Thai. 1992; 75: 236-9.
104. Canepa G, Di Somma C, Arnulfo G, Frascio M, Berti Riboli E. Studio retrospective sull' efficacia del trattamento della dispepsia funzionale. Minerva Medica. 1991; 82: 371-3 (In Italian with English abstract).
105. Hirayama A et al. The effect of combined Acenalin and Nauzelin in chronic gastritis. Med. Consult. New Remed. 1990; 27: 161-6.
106. Lee OY, Ahn JH, Rhee JC et al. The effects of domperidone on chronic hepatitis patients with dysfunctional upper gastroin-testinal symptoms. Korean J. Gastroenterol. 1990; 22: 394-400.
107. Bailey RJ, Mousseau R. Clinical evaluation of domperidone in the treatment of functional upper GI symptomatology. Today's Ther. Trends 1990; 7: 1-11.
108. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stotte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442-7.
109. Sheu BS, Lin CY, Lin XZ, Shiesh SC, Yang HB, Chen CY. Long-term outcome of triple therapy in Helicobacter pylori-related non-ulcer dyspepsia: A prospective controlled assessment. Am. J. Gastroenterol. 1996; 91: 441-7.
110. Frazzoni M, Lonardo A, Grisendi A. Are routine duodenal and antral biopsies useful in the management of functional dys-pepsia? J. Clin. Gastroenterol. 1993; 17: 101-18.
111. Nafeeza MI, Shahimi MM, Kudva MV et al. Evaluation of therapies in the treatment of Helicobacter pylori associated non-ulcer dys-pepsia. Singapore Med. J. 1992: 33: 570-4.
112. Schutze K, Hentschel E, Hirschl AM. Clarithromycin or amoxycillin plus high-dose ranitidine in the treatment of Hp positive functional dyspepsia. Eur. J. Gastroenterol. Hepatol. 1996; 8: 41-6.
113. Velanovich V. A prospective study of Helicobacter pylori nonulcer dyspepsia. Mil. Med. 1996; 161: 197-9.
114. Elta GH, Scheiman JM, Barnett JL et al. Long-term follow-up of Helicobacter pylori treatment in non-ulcer dyspepsia. Am. J. Gastroenterol. 1995; 90: 1089-93.
115. McCarthy et al. Long-term prospective study of Helicobacter pylori in non-ulcer dyspepsia. Dig. Dis. Sci. 1995; 40: 114-19.
116. Trespi E, Broglia F, Villani L, Luinetti O, Fiocca R, Solcia E. Distinct profiles of gastritis in dyspepsia subgroups. Their different clinical responses to gastritis healing after H. pylon eradication. Scand. J. Gastroenterol. 1994; 29: 884-8.
117. Sabbatini et al. The long-term outcome of dyspeptic patients after Helicobacter pylori eradication. Gastroenterol. 1993; 104: 182.
118. Holcombe C, Thom C, Kaluba, J, Lucas SB. Helicobacter pylon clearance in the treatment of non-ulcer dyspepsia. Aliment. Pharmacol. Ther. 1992; 6: 119-23.
119. Patchett S, Beattie S, Leen E, Keane C, O'Moraln C. Eradicating H. pylon and symptoms of non-ulcer dyspepsia. BMJ 1991; 303: 1238-40.
120. Petrino et al. Cure of chronic dyspepsia with eradication of Helicobacter pylori infection. Ital. J. Gastroenterol. 1991; 23 (Suppl): 213.
121. Petrolani et al. Non-ulcer dyspepsia, is there any correlation between clinical symptoms and histopathological features? Ital. J. Gastroenterol. 1991; 23 (Suppl): 217.
122. Talley NJ. Functional dyspepsia: Should treatment be targeted on disturbed physiology'? Aliment. Pharmacol. Ther. 1995; 9: 107-15.
123. Olsen AD, Deutsch D. Combined empiric treatment and specific H. pylori screening and treatment decrease the cost of evaluating epigastric abdominal pain. Gastroenterology 1998; (in press) 114: A.